TrialAMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Trial details
- Registry ID
- NCT03127514
- Phase
- Phase 2
AMLX
Amylyx Pharmaceuticals Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
8Trials in this database
9Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03127514 | AMLX | Phase 2 | Completed | 2019-09-25Actual |
| Open Label Extension Study of AMX0035 in Patients With ALSNCT03488524 | AMLX | Phase 2 | Completed | 2021-03-01Actual |
| Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's DiseaseNCT03533257 | AMLX | Phase 2 | Completed | 2020-10-22Actual |
| Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentNCT05021536 | AMLX | Phase 3 | Unknown | 2024-01-19Actual |
| Extension Study Evaluating The Safety And Tolerability of AMX0035NCT05619783 | AMLX | Phase 3 | Completed | 2024-10-16Actual |
| AMX0035 in Adult Patients With Wolfram SyndromeNCT05676034 | AMLX | Phase 2 | Active not recruiting | 2024-07-23Actual |
| AMX0035 and Progressive Supranuclear PalsyNCT06122662 | AMLX | Phase 2, Phase 3 | Completed | 2025-09-30Actual |
| Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468 | AMLX | Phase 3 | Active not recruiting | 2026-07-08Actual |
Open Label Extension Study of AMX0035 in Patients With ALS
Trial details
- Registry ID
- NCT03488524
- Phase
- Phase 2
Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
Trial details
- Registry ID
- NCT03533257
- Phase
- Phase 2
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Trial details
- Registry ID
- NCT05021536
- Phase
- Phase 3
Extension Study Evaluating The Safety And Tolerability of AMX0035
Trial details
- Registry ID
- NCT05619783
- Phase
- Phase 3
AMX0035 in Adult Patients With Wolfram Syndrome
Trial details
- Registry ID
- NCT05676034
- Phase
- Phase 2
AMX0035 and Progressive Supranuclear Palsy
Trial details
- Registry ID
- NCT06122662
- Phase
- Phase 2, Phase 3
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Trial details
- Registry ID
- NCT06747468
- Phase
- Phase 3
Latest recorded trial changes
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468 · Amylyx Pharmaceuticals Inc.
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2026-03
+ Updated value
2026-07-08
AMX0035 and Progressive Supranuclear Palsy
NCT06122662 · Amylyx Pharmaceuticals Inc.
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 110; type: ESTIMATED
+ Updated value
count: 139; type: ACTUAL
Completion date type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Primary completion date
Recorded edit− Previous value
2026-04-01
+ Updated value
2025-09-30
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Completed
AMX0035 in Adult Patients With Wolfram Syndrome
NCT05676034 · Amylyx Pharmaceuticals Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT); measure: To assess the safety and tolerability of AMX0035 administered orally for up to 144 weeks in adult participants with Wolfram syndrome
+ Updated value
measure: To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT); measure: To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndrome
The saved outcome text may be shortened. Check the source for full wording.
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468 · Amylyx Pharmaceuticals Inc.
Recruitment status
Recorded edit− Previous value
Recruiting
+ Updated value
Active not recruiting